Affini-T Therapeutics

Affini T Therapeutics

Biotechnology, 343 Arsenal St, Watertown, Massachusetts, 02472, United States, 51-200 Employees

affinittx.com

  • facebook
  • LinkedIn

Who is AFFINI-T THERAPEUTICS

Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiate...

Read More

map
  • 343 Arsenal St, Watertown, Massachusetts, 02472, United States Headquarters: 343 Arsenal St, Watertown, Massachusetts, 02472, United States
  • 2021 Date Founded: 2021
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from AFFINI-T THERAPEUTICS

Affini-T Therapeutics Org Chart and Mapping

Employees

Donovan Farris

Director of Manufacturing

Joseph Lee

Senior Director, Product Sciences

Julio Infante

Sr. IT Support Specialist

Sarah Vidyasagar

Research Associate II, Process Development

Damien Hallet

Vice President - Head of Cmc

Heather Cole

Head of Human Resources & Talent Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Affini-T Therapeutics

Answer: Affini-T Therapeutics's headquarters are located at 343 Arsenal St, Watertown, Massachusetts, 02472, United States

Answer: Affini-T Therapeutics's official website is https://affinittx.com

Answer: Affini-T Therapeutics's revenue is $10 Million to $25 Million

Answer: Affini-T Therapeutics's SIC: 2836

Answer: Affini-T Therapeutics's NAICS: 541714

Answer: Affini-T Therapeutics has 51-200 employees

Answer: Affini-T Therapeutics is in Biotechnology

Answer: Affini-T Therapeutics contact info: Phone number: Website: https://affinittx.com

Answer: Affini-T is a leading precision immunotherapy company targeting core oncogenic driver mutations to develop potentially curative therapies for patients with solid tumors. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology, and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access